<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026545</url>
  </required_header>
  <id_info>
    <org_study_id>B0581002</org_study_id>
    <nct_id>NCT01026545</nct_id>
  </id_info>
  <brief_title>Multiple Oral Dose Safety, Tolerability And Pharmacokinetic Study Of PF-04287881 In Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04287881 After Administration Of Multiple Escalating Oral Doses To Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, investigator blind, subject blind, sponsor-open, placebo
      controlled, multiple dose escalating, sequential, parallel cohort study of PF-04287881.
      Subjects will undergo screening procedures within 28 days prior to dosing. At least 1 day
      after the Screening visit, eligible subjects who meet the entry criteria will be admitted to
      the Clinical Research Unit (CRU) and confined in the unit until discharge on Day 15.

      Approximately 60 healthy volunteers (20 volunteers of Japanese origin for Cohorts 5 and 6),
      18 to 55 years of age, males and females (women of non childbearing potential only) will be
      enrolled and randomized in a 4:1 ratio to treatment with either PF-04287881 or placebo within
      each cohort. Each cohort will have a 10 day dosing period and each will consist of 10
      subjects (8 active and 2 placebo). In each cohort, each subject will receive a single daily
      oral dose of either placebo or PF-04287881 under fasted state for 10 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following a Serious Adverse Event (potential Hy's Law case), a risk-benefit assessment review
      of all preliminary safety data, and a review by Pfizer's internal hepatic injury advisory
      panel, it was concluded that PF-04287881 had an unacceptable therapeutic window. The FDA was
      notified of our intention to discontinue development as of 09April2010.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standard safety assessments including assessment of AEs, laboratory tests, ECGs, and vital signs.</measure>
    <time_frame>Screening, Dosing days 1-10, through follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary pharmacokinetic endpoints to be evaluated for PF-04287881 include Cmax, Tmax, and AUC(0-24) on Day 1 and Day 10.</measure>
    <time_frame>Day 1 and 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary parameters include AUCinf and t1/2 as data permit, apparent oral clearance (CL/F), apparent volume of distribution (Vz/F) and accumulation ratio (Rac).</measure>
    <time_frame>Days 1, 5 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine concentrations of PF 04287881 in Cohorts 2 and 5 will be used to determine total amount excreted (Ae), %Ae relative to dose given and renal clearance (CLR).</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of PF 04287881 will be measured in white blood cell (WBC) polymorphonuclear cells (PMNs) in Cohorts 2 and 5 to determine total exposure in WBC.</measure>
    <time_frame>Days 1 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma samples from Cohort 2 will be used for exploratory investigation of circulating metabolites.</measure>
    <time_frame>Days 1 and 10</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If intermediate or repeat dose level is needed; dose will not exceed 1100 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 (Japanese)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 (Japanese)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04287881</intervention_name>
    <description>500 mg once daily for 10 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>To match 500 mg dose once daily for 10 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04287881</intervention_name>
    <description>750 mg once daily for 10 days</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>To match 750 mg dose once daily for 10 days</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04287881</intervention_name>
    <description>1100 mg once daily for 10 days</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>To match 1100 mg dose once daily for 10 days</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04287881</intervention_name>
    <description>Optional cohort with dose not greater than 1100 mg</description>
    <arm_group_label>Cohort 4 (optional)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Optional cohort to match dose not greater than 1100 mg</description>
    <arm_group_label>Cohort 4 (optional)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04287881</intervention_name>
    <description>750 mg dose once daily for 10 days</description>
    <arm_group_label>Cohort 5 (Japanese)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>To match 750 mg dose once daily for 10 days</description>
    <arm_group_label>Cohort 5 (Japanese)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04287881</intervention_name>
    <description>1100 mg dose once daily for 10 days</description>
    <arm_group_label>Cohort 6 (Japanese)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>To match 1100 mg dose once daily for 10 days</description>
    <arm_group_label>Cohort 6 (Japanese)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Volunteers willing and able to be confined to the Clinical Research Unit and comply
             with study schedule.

          -  Women of non-childbearing potential only.

          -  Japanese subjects must have 4 Japanese grandparents who were born in Japan.

        Exclusion Criteria:

          -  Previous antibiotic use within 14 days prior to dosing.

          -  Use of antibiotics during hospitalization within 90 days prior to dosing.

          -  History of hypersensitivity to macrolides or ketolides.

          -  Presence of clinically significant eye conditions (other than corrective lenses).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0581002&amp;StudyName=Multiple%20Oral%20Dose%20Safety%2C%20Tolerability%20And%20Pharmacokinetic%20Study%20Of%20PF-04287881%20In%20Healthy%20Adult%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <last_update_submitted>May 3, 2011</last_update_submitted>
  <last_update_submitted_qc>May 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>multiple-dose</keyword>
  <keyword>macrolide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

